ASIATODAY.ID, JAKARTA — Indonesia is accelerating its transformation into a high-value healthcare economy as Japan’s pharmaceutical leader Takeda Pharmaceutical Company commits up to US$30 million to develop a national ecosystem for plasma-derived products (PDP).
The investment, equivalent to approximately IDR539 billion, represents a strategic move beyond conventional manufacturing cooperation, positioning Indonesia as an emerging player in Asia’s fast-growing biotechnology and pharmaceutical landscape.
The project will initially focus on establishing a plasma bank network over a two-year period, creating the foundation for a domestic plasma-based pharmaceutical industry that meets international standards.
The first plasma bank is targeted to begin operations in 2027, supporting Indonesia’s efforts to strengthen healthcare resilience, improve access to essential therapies and participate more deeply in the global pharmaceutical supply chain.
A New Era of Indonesia-Japan Economic Partnership
Indonesia’s Minister of Investment and Downstreaming and Head of the Investment Coordinating Board (BKPM) Rosan Roeslani said Takeda’s commitment reflects increasing global confidence in Indonesia’s economic potential.
“This investment is strategic because it brings not only capital, but also technology transfer, human resource development and high-skilled employment opportunities,” Rosan said.
According to Rosan, the partnership aligns with Indonesia’s strategy to accelerate economic transformation through downstream industries with higher added value, including healthcare, biotechnology and advanced manufacturing.
Indonesia Moves Beyond Commodity-Based Growth
For decades, Indonesia’s economic growth has been closely associated with natural resources. However, Jakarta is now seeking to build new engines of growth based on innovation, technology and knowledge-intensive industries.
The healthcare sector has become a strategic priority as countries across Asia compete to secure pharmaceutical supply chains and reduce vulnerability to global disruptions.
Takeda’s investment is expected to help Indonesia develop capabilities across the healthcare value chain — from plasma collection and processing to technology development and skilled workforce creation.
Japan Remains a Strategic Investment Partner
The investment also reinforces Japan’s long-standing role as one of Indonesia’s key economic partners.
Indonesia’s investment authority recorded Japanese investment of around US$1 billion in the first quarter of 2026, placing Japan among the country’s top five foreign investors.
Between 2021 and the first quarter of 2026, total Japanese investment in Indonesia reached US$18.1 billion, growing by an average of 13.2 percent and contributing to employment for nearly 300,000 workers.
The latest commitment signals a shift in bilateral cooperation — from traditional industrial investment toward innovation-driven sectors that will shape the future economy.
Competing for Asia’s Biopharmaceutical Future
Across Asia, governments are racing to attract biotechnology investment, strengthen medical supply chains and build domestic pharmaceutical capabilities.
With its large population, expanding healthcare demand and growing industrial base, Indonesia is positioning itself as more than a consumer market — but as a potential regional production and innovation center.
The Takeda partnership represents a milestone in that journey.
Indonesia’s ambition is clear: to move from importing healthcare solutions to becoming part of the global ecosystem that creates them. (AT Network)
Follow Us at Google News, Instagram, WA Channel, and LinkedIn